Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.

Vaccines have been approved – so why are we still developing others?

The COVID-19 vaccines currently rolling off production lines have been developed faster than any other vaccine against a new disease in history. How have scientists achieved this incredible feat? And could the lessons learned enable more rapid…

The best way we can prevent flu infection is by getting vaccinated. The problem with the flu vaccine is that in some years it doesn’t work as well as others.

Coronavirus can survive on surfaces, so should unwrapping presents be considered risky? We examine the evidence.

A second typhoid conjugate vaccine has achieved WHO prequalification and others are in development. More vaccines will help increase access to TCVs.

12 charts provide an overview of our research in the face of a truly unprecedented crisis.

Some of the COVID-19 vaccines use messenger RNA to provoke an immune response. But what exactly is this genetic material, and how does it interact with the DNA in our cells?

As the new COVID-19 vaccines begin to ship out, how ready are health systems to manage delivery? Here are four ways countries should frame that question.

New girl-centered toolkit helps health officials develop and implement communications campaigns that resonate with girls in their countries.

High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.

Community mobilizers inform and prepare communities for vaccinators.